Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Fosun Pharmaceutical
YSB Inc. Lists on HKSE with HKD 363.6 Million IPO, Targeting Digital Pharma Services
China-based ex-hospital digital pharmaceutical service platform YSB Inc. (HKG: 9885) has successfully made its initial...
Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study
Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...
Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China
China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...
Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma
Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co.,...
Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...
Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...
Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...
ConjuStar Peptide-Drug Conjugate Angel Financing
Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...
Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...
Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US
US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc.,...
Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China
The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...
Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...
Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...
Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...